Ian F Hermans

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
    Ian F Hermans
    Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5140-7. 2003
  2. pmc Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
    Jonathan D Silk
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Clin Invest 114:1800-11. 2004
  3. ncbi request reprint The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo
    Ian F Hermans
    Tumour Immunology Unit, Nuffield Department of Medicine, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    J Immunol Methods 285:25-40. 2004
  4. ncbi request reprint Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells
    Ian F Hermans
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 178:2721-9. 2007
  5. pmc CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens
    Mariolina Salio
    Cancer Research Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, OX3 9DS Oxford, UK
    J Exp Med 199:567-79. 2004
  6. ncbi request reprint Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model
    Ian F Hermans
    Tumour Immunology Unit, Cancer Research UK, University of Oxford, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 63:8408-13. 2003
  7. ncbi request reprint High avidity antigen-specific CTL identified by CD8-independent tetramer staining
    Ed Man Lik Choi
    Tumour Immunology Unit, Nuffield Department of Medicine, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5116-23. 2003
  8. ncbi request reprint Dendritic cells: a journey from laboratory to clinic
    Vincenzo Cerundolo
    Tumour Immunology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Nat Immunol 5:7-10. 2004
  9. ncbi request reprint Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity
    Adrianne Lee
    Carbohydrate Chemistry, Industrial Research Limited, PO Box 31 310, Lower Hutt, New Zealand
    Carbohydr Res 341:2785-98. 2006
  10. ncbi request reprint 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy
    Kate E Matthews
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Immunol Cell Biol 84:383-9. 2006

Collaborators

Detail Information

Publications14

  1. ncbi request reprint NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
    Ian F Hermans
    Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5140-7. 2003
    ..Thus, iNKT cells exert a significant influence on the efficacy of immune responses to soluble Ag by modulating DC function...
  2. pmc Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
    Jonathan D Silk
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Clin Invest 114:1800-11. 2004
    ....
  3. ncbi request reprint The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo
    Ian F Hermans
    Tumour Immunology Unit, Nuffield Department of Medicine, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    J Immunol Methods 285:25-40. 2004
    ..The VITAL assay is, therefore, a sensitive technique allowing analysis of complex multi-epitope responses...
  4. ncbi request reprint Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells
    Ian F Hermans
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 178:2721-9. 2007
    ..These studies highlight the potential for manipulating the interactions between TLR ligands and iNKT cell activation in the design of effective vaccine adjuvants...
  5. pmc CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens
    Mariolina Salio
    Cancer Research Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headley Way, OX3 9DS Oxford, UK
    J Exp Med 199:567-79. 2004
    ....
  6. ncbi request reprint Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model
    Ian F Hermans
    Tumour Immunology Unit, Cancer Research UK, University of Oxford, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 63:8408-13. 2003
    ..The combination of immunotherapy and metronomic CTX therapy may be well suited to clinical management of cancer...
  7. ncbi request reprint High avidity antigen-specific CTL identified by CD8-independent tetramer staining
    Ed Man Lik Choi
    Tumour Immunology Unit, Nuffield Department of Medicine, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5116-23. 2003
    ....
  8. ncbi request reprint Dendritic cells: a journey from laboratory to clinic
    Vincenzo Cerundolo
    Tumour Immunology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Nat Immunol 5:7-10. 2004
  9. ncbi request reprint Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity
    Adrianne Lee
    Carbohydrate Chemistry, Industrial Research Limited, PO Box 31 310, Lower Hutt, New Zealand
    Carbohydr Res 341:2785-98. 2006
    ..This synthesis strategy will permit the generation of novel derivatives for use in the study of the mechanism of iNKT cell activation...
  10. ncbi request reprint 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy
    Kate E Matthews
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Immunol Cell Biol 84:383-9. 2006
    ..It is possible that this lack of synergism may result from both treatments inducing activation of CD8+ T cells and that treatments that activate different populations of immune cells may achieve better success...
  11. pmc Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo
    Jianping Yang
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Proc Natl Acad Sci U S A 103:147-52. 2006
    ..Our data suggest that CTL act as "gatekeepers" that control access of antigen-loaded DC into the lymph node, thereby preventing continued expansion of antigen-specific T cells...
  12. ncbi request reprint Competition between CTL narrows the immune response induced by prime-boost vaccination protocols
    Michael J Palmowski
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 168:4391-8. 2002
    ..Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response...
  13. ncbi request reprint Tumor immunotherapy by epicutaneous immunization requires langerhans cells
    Patrizia Stoitzner
    Malaghan Institute of Medical Research, Wellington, New Zealand
    J Immunol 180:1991-8. 2008
    ..The topically applied Ag was presented by skin-derived LC in draining lymph nodes to CD8(+) T cells. Thus, targeting of tumor Ags to LC in vivo is an effective strategy for tumor immunotherapy...
  14. ncbi request reprint Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses
    Kate E Matthews
    Malaghan Institute of Medical Research, Wellington, New Zealand
    J Immunol 179:5738-47. 2007
    ..We conclude that CD4(+) T cell help for CD8(+) responses involves mechanisms other than the increased survival of Ag-presenting DC in the lymph node...